Accessibility Menu
Remedent logo

Remedent(OTC) REMI

Market Cap$14.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-100%
1 Year-93%
1 Month+0%
$0.00
+0.00%
+0.00Today
Remedent last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-09
Remedent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-01-30
1 month+0%USD 0.002026-01-30
3 month+0%USD 0.002026-01-30
Year to date+16.67%USD 0.002025-12-19
1 year-93%USD 0.012025-07-09
3 year-99.59%USD 0.172023-06-30
5 year-99.65%USD 0.202021-06-11
Since inception-100%USD 58.131998-10-22

Remedent Financials at a Glance

Market Cap

$14.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$986.22K

Net Income (TTM)

-$274.45K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.44 (Low)

Price

$0.00

Volume

20

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Nov 27, 2024

REMI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing, and distribution of innovative products for oral hygiene and aesthetic dentistry. The company offers professional-grade dental veneers and teeth whitening systems, catering to both dental practitioners and consumers.

Products and Services
  • Professional-grade dental veneers for aesthetic enhancement
  • Teeth whitening systems for dental practices and consumers
  • Digital tools like SmileMe Mirror and SmileSketch for dental consultations
Growth Outlook
  • Revenue increased to $253,932 in Q4 2024, showing potential for growth
  • Gross profit margin improved to 63.6% in Q4 2024, indicating operational efficiency
  • Expansion into nearly 30 countries enhances market reach and sales opportunities
Financial Highlights
  • Trailing twelve months revenue of $1,086,240 reflects a steady demand for products
  • Net income for Q4 2024 was -$219,340, highlighting ongoing challenges
  • Cash and cash equivalents stood at $43,304 as of March 31, 2024
Remedent, Inc. operates in the medical instruments and supplies industry, focusing on dental solutions that enhance both functionality and aesthetics. The company’s innovative product offerings, such as the River8 veneer solution and GlamSmile veneers, are designed to meet the evolving needs of dental professionals and consumers alike. The digital tools provided by Remedent further streamline dental practice operations, making consultations more efficient and effective. Despite recent financial challenges, including a net loss in the latest quarter, the company has shown resilience with a notable increase in revenue and gross profit margins. The expansion into international markets positions Remedent for potential growth, as it continues to innovate and adapt to the dental industry's demands. Investors may find interest in the company's strategic direction and product development as it seeks to enhance its market presence.
AI Generated • Aug 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

4

CEO

Guy de Vreese

Website

www.remedent.com

Headquarters

Gent, VL 9000, BE

REMI Financials

Key Financial Metrics (TTM)

Gross Margin

61.17%

Operating Margin

-12.46%

Net Income Margin

-27.83%

Return on Equity

-11.26%

Return on Capital

-5.35%

Return on Assets

-5.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.00M

Volume

20

Avg. Volume

0.318

Financials (TTM)

Gross Profit

$603.24K

Operating Income

-$122.90K

EBITDA

-$212.84K

Operating Cash Flow

-$130.51K

Capital Expenditure

$5.00

Free Cash Flow

-$130.51K

Cash & ST Invst.

$43.30K

Total Debt

$15.48K

Remedent Performance Analysis

Remedent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 1,407,661N/A
20232023-03-31USD 863,819-38.6%
20242024-03-31USD 986,22014.2%
Remedent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-06-304.4%
Q22023-09-30-14.7%
Q32023-12-3178.1%
Q42024-03-31-23.0%
Remedent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -0.01N/A
20232023-03-31USD -0.07479.8%
20242024-03-31USD -0.01-81.7%
Remedent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-06-3087.6%
Q22023-09-3051.6%
Q32023-12-31220.0%
Q42024-03-31-711.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$253.93K

+22.0%

Gross Profit

$161.61K

+43.1%

Gross Margin

63.64%

N/A

Market Cap

$14.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.67K

N/A

Employees

3

N/A

Net Income

-$219.34K

+56.0%

EBITDA

-$204.54K

+58.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$43.30K

-58.9%

Total Debt

$15.48K

N/A

Accounts Receivable

$868.91K

+20.3%

Inventory

$91.88K

-1.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$15.48K

-61.6%

Return on Assets

-5.00%

N/A

Return on Invested Capital

-5.02%

N/A

Free Cash Flow

-$92.50K

-240.7%

Operating Cash Flow

-$92.50K

-240.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VICARafina Innovations Inc.
$0.00+0.00%
THCTTHC Therapeutics, Inc.
$0.00+0.00%
EMGEEmergent Health Corp
$0.00+0.00%
CYPSCyclo3pss Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About REMI

What is the current price of Remedent?

Remedent is trading at $0.00 per share.

What is the 52-week range for Remedent?

Over the past 52 weeks, Remedent has traded between $0.00 and $0.01.

How much debt does Remedent have?

As of the most recent reporting period, Remedent reported total debt of $0.00.

How much cash does Remedent have on hand?

Remedent reported $43.30K in cash and cash equivalents in its most recent financial results.

What is Remedent’s dividend yield?

Remedent does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services